Rivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism Chen T et al. - Rivaroxaban is a novel oral direct factor Xa inhibitor. Rivaroxaban has been shown to have tolerable adverse effects and a low potential for drug-drug or drug-food interactions. It has the major advantages of once daily oral dosing and no required laboratory monitoring, giving it the potential to replace current antithrombotics in the market today. [more...]
